Kelun-Biotech completes HK$2.72 billion H-share placement at HK$470.2 per share

• Sichuan Kelun-Biotech Biopharmaceutical completed a private placement of 5,838,000 new H shares on July 10, 2026.
• Shares priced at HK$ 470.2 each; net proceeds about HK$ 2.72 billion.
• Proceeds earmarked mainly for R&D and clinical development, with smaller allocations for pipeline expansion and working capital.
• Total shares outstanding rose to 239,023,969; Kelun Pharmaceutical stake diluted to 62.53% from 64.1%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12240994), on July 10, 2026, and is solely responsible for the information contained therein.